News
Aytu BioPharma Appoints Mark Oki as Chief Financial Officer
ENGLEWOOD, CO / January 4, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, today announced that Mark Oki will join Aytu as the company's chief financial officer...
Aytu BioPharma to Present at H.C. Wainwright BioConnect Conference
ENGLEWOOD, CO / January 3, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, today announced that Josh Disbrow, chief executive officer of Aytu, will present a...
Aytu BioPharma Announces FDA Clearance of Investigational New Drug (IND) Application for AR101/Enzastaurin in Vascular Ehlers-Danlos Syndrome
Pivotal clinical trial will begin in first half of 2022ENGLEWOOD, CO / December 13, 2021 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, today announced that the U.S. Food...
Aytu BioPharma Receives Orphan Drug Designation from FDA for AR101 for Treatment of Vascular Ehlers-Danlos Syndrome
ENGLEWOOD, CO / December 8, 2021 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, today announced that the U.S. Food and Drug Administration (FDA) has granted...
Aytu BioPharma Announces Issuance of First U.S. Patent Supporting Healight Ultraviolet-A Respiratory Catheter
ENGLEWOOD, CO / November 23, 2021 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, announced that today the United States Patent and Trademark Office (USPTO) has...
Aytu BioPharma Ranked Number 178 Fastest-Growing Company in North America on the 2021 Deloitte Technology Fast 50™
ENGLEWOOD, CO / November 17, 2021 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, today announced it ranked 178 on the Deloitte Technology Fast 500™, a...
Aytu BioPharma Reports First Quarter 2022 Financial Results
Quarterly net revenue increased 62% to $21.9 millionEnded quarter with approximately $40.6 million in cash, cash equivalents and restricted cashFully integrated and expanding RxConnect patient support program and salesforce drove growth across prescription...
Aytu BioPharma to Report First Quarter Fiscal 2022 Results and Provide Business Update on November 15, 2021
ENGLEWOOD, CO / November 8, 2021 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, announced today that it will host a conference call and live webcast on November...
CORRECTION: Aytu BioPharma to Present at Upcoming September Investor Conferences
(This release corrects the previous one that was issued on September 7, 2021 to reflect the time of the Cantor Presentation being changed to 2:40 pm EST)ENGLEWOOD, CO / September 30, 2021 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused...
Aytu BioPharma Reports Fourth Quarter and Full-Year Fiscal 2021 Financial Results
Quarterly net revenue increased 74% sequentially to $23.5M; 138% year-over-year to $65.6MEnded quarter with approximately $50M in cash, cash equivalents and restricted cashPlanned pivotal study for AR101 in Vascular Ehlers-Danlos Syndrome (VEDS) to begin in 1H22;...